Enanta Pharmaceuticals Valuation
| ENTA Stock | USD 13.89 0.03 0.22% |
At this time, the firm appears to be undervalued. Enanta Pharmaceuticals shows a prevailing Real Value of $17.21 per share. The current price of the firm is $13.89. Our model computes the value of Enanta Pharmaceuticals from reviewing the firm fundamentals such as Current Valuation of 273.14 M, operating margin of (0.60) %, and Profit Margin of (1.07) % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Enanta Pharmaceuticals' valuation include:
Price Book 3.1749 | Enterprise Value | Enterprise Value Ebitda (0.29) | Price Sales 6.0656 | Enterprise Value Revenue 4.0779 |
Undervalued
Today
Please note that Enanta Pharmaceuticals' price fluctuation is not too volatile at this time. Calculation of the real value of Enanta Pharmaceuticals is based on 3 months time horizon. Increasing Enanta Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Enanta Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Enanta Stock. However, Enanta Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 13.89 | Real 17.21 | Target 20.25 | Hype 13.79 | Naive 13.73 |
The real value of Enanta Stock, also known as its intrinsic value, is the underlying worth of Enanta Pharmaceuticals Company, which is reflected in its stock price. It is based on Enanta Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Enanta Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Enanta Pharmaceuticals helps investors to forecast how Enanta stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Enanta Pharmaceuticals more accurately as focusing exclusively on Enanta Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Enanta Pharmaceuticals' intrinsic value based on its ongoing forecasts of Enanta Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Enanta Pharmaceuticals' closest peers. If more than one evaluation category is relevant for Enanta Pharmaceuticals we suggest using both methods to arrive at a better estimate.
Enanta Pharmaceuticals Cash |
|
Enanta Pharmaceuticals Total Value Analysis
Enanta Pharmaceuticals is currently anticipated to have valuation of 273.14 M with market capitalization of 406.27 M, debt of 201.06 M, and cash on hands of 253.29 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Enanta Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
273.14 M | 406.27 M | 201.06 M | 253.29 M |
Enanta Pharmaceuticals Investor Information
About 91.0% of the company shares are held by institutions such as insurance companies. The book value of Enanta Pharmaceuticals was currently reported as 4.36. The company has Price/Earnings (P/E) ratio of 366.13. Enanta Pharmaceuticals recorded a loss per share of 3.24. The entity had not issued any dividends in recent years. Based on the key indicators related to Enanta Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Enanta Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Enanta Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Enanta Pharmaceuticals has an asset utilization ratio of 23.27 percent. This suggests that the Company is making $0.23 for each dollar of assets. An increasing asset utilization means that Enanta Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Enanta Pharmaceuticals Profitability Analysis
Based on Enanta Pharmaceuticals' profitability indicators, Enanta Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Enanta Pharmaceuticals' ability to earn profits and add value for shareholders.Net Loss | First Reported 2010-09-30 | Previous Quarter -18.7 M | Current Value -11.9 M | Quarterly Volatility 21.4 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.74 | 0.84 |
|
|
For Enanta Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Enanta Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Enanta Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Enanta Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Enanta Pharmaceuticals over time as well as its relative position and ranking within its peers.
Enanta Pharmaceuticals Earnings per Share Projection vs Actual
The next projected EPS of Enanta Pharmaceuticals is estimated to be -0.5575 with future projections ranging from a low of -0.67 to a high of -0.51. Enanta Pharmaceuticals' most recent 12-month trailing earnings per share (EPS TTM) is at -3.24. Please be aware that the consensus of earnings estimates for Enanta Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Enanta Pharmaceuticals Earnings Estimation Breakdown
The calculation of Enanta Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Enanta Pharmaceuticals is estimated to be -0.5575 with the future projection ranging from a low of -0.67 to a high of -0.51. Please be aware that this consensus of annual earnings estimates for Enanta Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.67 Lowest | Expected EPS | -0.51 Highest |
Enanta Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Enanta Pharmaceuticals' value are higher than the current market price of the Enanta Pharmaceuticals stock. In this case, investors may conclude that Enanta Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Enanta Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2026 | Current EPS (TTM) | |
| 7 | 73.21% | 0.0 | -0.5575 | -3.24 |
Enanta Pharmaceuticals Ownership Allocation
Enanta Pharmaceuticals holds a total of 29.02 Million outstanding shares. The majority of Enanta Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Enanta Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Enanta Pharmaceuticals. Please pay attention to any change in the institutional holdings of Enanta Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Enanta Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 65.32 M. Net Loss for the year was (81.89 M) with profit before overhead, payroll, taxes, and interest of 66.98 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Enanta Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Enanta Pharmaceuticals and how it compares across the competition.
About Enanta Pharmaceuticals Valuation
The stock valuation mechanism determines Enanta Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Enanta Pharmaceuticals. We calculate exposure to Enanta Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Enanta Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 69.8 M | 100.6 M | |
| Pretax Profit Margin | (1.47) | (1.40) | |
| Operating Profit Margin | (1.50) | (1.43) | |
| Net Loss | (1.44) | (1.37) | |
| Gross Profit Margin | 0.84 | 0.74 |
Enanta Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 21.3 M | |
| Quarterly Earnings Growth Y O Y | -0.662 |
Enanta Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Enanta Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Enanta we look at many different elements of the entity such as Enanta's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Enanta Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Enanta Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Enanta Pharmaceuticals' worth.Complementary Tools for Enanta Stock analysis
When running Enanta Pharmaceuticals' price analysis, check to measure Enanta Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enanta Pharmaceuticals is operating at the current time. Most of Enanta Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Enanta Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enanta Pharmaceuticals' price. Additionally, you may evaluate how the addition of Enanta Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |